Single Use Bioprocessing Market Set to Hit USD 104.1 Billion by 2034 from USD 32.0 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - As biopharmaceutical manufacturers shift away from capital-intensive stainless-steel infrastructure toward disposable production lines, that transition is emerging as one of the defining forces reshaping capacity planning across the industry. According to a new report from Strategic Revenue Insights, the single use bioprocessing market was valued at USD 32.0 billion in 2025 and is projected to reach USD 104.1 billion by 2034, growing at a CAGR of 14.00% during the forecast period. The findings are led by analyst Sandeepa Kulkarni, and the report draws on primary interviews with bioprocessing engineers, biopharmaceutical manufacturers, and contract development and manufacturing organization executives, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The single use bioprocessing market is valued at USD 32.0 billion in 2025 and is forecast to reach USD 104.1 billion by 2034, a CAGR of 14.00%.
• Single-Use Bioreactors are the largest product type segment, while Cell & Gene Therapy is the fastest-growing application segment.
• Digital transformation, including IoT, automation, and real-time monitoring, is reshaping bioprocessing operations and improving efficiency.
• North America leads the market on the strength of advanced healthcare infrastructure, while Asia Pacific is the fastest-growing region.
• Sartorius, Danaher (via Cytiva and Pall), and Thermo Fisher Scientific are the top competitors named in the report.

Full report access: https://www.strategicrevenueinsights.com/industry/single-use-bioprocessing-market

From Stainless Steel to Single-Use: Manufacturing Flexibility Takes Center Stage

The clearest driver behind the market's expansion is the growing demand for biologics, including monoclonal antibodies and vaccines, which require production processes that can scale quickly without the capital burden of traditional stainless-steel systems. Single-use technologies reduce contamination risk and shorten changeover time between production runs, advantages that became especially visible during the COVID-19 pandemic, when manufacturers needed to pivot capacity rapidly. Government initiatives aimed at expanding domestic biopharmaceutical production capacity are reinforcing this shift, as are regional capacity-building programs designed to reduce dependence on a small number of concentrated manufacturing geographies.

Sustainability is becoming a parallel driver rather than a side consideration. Manufacturers are investing in biodegradable and recyclable single-use components in response to both regulatory pressure and buyer demand for environmentally responsible products, and companies that move first on this front are positioning themselves for a competitive advantage. At the same time, digital transformation, spanning data analytics, IoT connectivity, and automation, is being layered onto single-use workflows to enable real-time monitoring, reduce downtime, and improve product consistency.

The market's growth is not without friction. The upfront cost of single-use systems relative to stainless-steel equipment remains a meaningful barrier for smaller manufacturers, and outsourcing to contract development and manufacturing organizations is one way sponsors are converting fixed capital costs into variable spending. Even so, the combination of expanding biologics and advanced therapy pipelines with intensified, single-use processing technologies is expected to keep demand climbing through 2034.

Market Segmentation

By product type, Single-Use Bioreactors hold the largest share, reflecting their broad adoption across biopharmaceutical production, while Chromatography Devices are gaining momentum as demand grows for high-purity biologics and more efficient separation and purification processes.

By workflow stage, Upstream Processing leads given its central role in biopharmaceutical production, while Fill-Finish and Media & Buffer Preparation are gathering share as manufacturers seek precise, reliable, and contamination-resistant processes further down the production chain.

By application, Monoclonal Antibody Production is the largest segment, underpinned by its widespread use across biopharmaceutical manufacturing, while Cell & Gene Therapy is the fastest-growing application as personalized medicine expands the need for flexible, small-batch production.

By end use, Pharmaceutical Companies represent the largest share of demand given their scale of investment in biopharmaceutical manufacturing, while Hospitals & Clinics and Contract Development & Manufacturing Organizations are increasingly adopting single-use systems as personalized medicine and advanced therapies expand.

Regional Outlook

North America is the leading region in the single use bioprocessing market, supported by advanced healthcare infrastructure and high adoption of single-use technologies among established manufacturers. Asia Pacific is the fastest-growing region, driven by rapid expansion of the biopharmaceutical industry and rising investment in healthcare infrastructure, prompting global players to expand their regional presence. Europe continues to represent a substantial share of demand alongside established biopharmaceutical manufacturing hubs, while Latin America and Middle East & Africa are earlier in their adoption curves but are benefiting from the same capacity-building investments driving growth in Asia Pacific.

Competitive Landscape

The market remains concentrated among a small number of established suppliers. Sartorius is recognized for its broad portfolio of single-use technologies and a strong emphasis on innovation and sustainability, which has helped it maintain a leading position with biopharmaceutical manufacturers worldwide. Danaher, operating through its Cytiva and Pall subsidiaries, offers a wide range of single-use systems across bioprocessing applications and has built its position through sustained investment in research and development. Thermo Fisher Scientific rounds out the group of leading suppliers, drawing on an extensive product portfolio and global footprint to serve manufacturers across regions.

Market Restraints

Two factors stand out as the primary restraints on market growth. First, the higher upfront cost of single-use systems relative to traditional stainless-steel equipment can be a barrier for small and medium-sized manufacturers, requiring suppliers to demonstrate long-term cost benefits to win adoption. Second, stringent regulatory requirements for biopharmaceutical manufacturing, combined with a lack of standardization across single-use technologies, can slow adoption and complicate compatibility between systems from different suppliers.

Related Reports

https://www.strategicrevenueinsights.com/industry/enterprise-resource-planning-erp-software-market

https://www.strategicrevenueinsights.com/industry/environmental-monitoring-market

https://www.strategicrevenueinsights.com/industry/equipment-monitoring-market

https://www.strategicrevenueinsights.com/industry/generative-ai-market

https://www.strategicrevenueinsights.com/industry/generative-ai-in-enterprise-software-market

Frequently Asked Questions

How big is the single use bioprocessing market?

The market was valued at USD 32.0 billion in 2025 and is projected to reach USD 104.1 billion by 2034, growing at a CAGR of 14.00%.

What is the fastest-growing segment in single use bioprocessing?

Cell & Gene Therapy is the fastest-growing application segment, driven by advancements in personalized medicine that require flexible, small-batch production.

Which region leads the single use bioprocessing market?

North America is the leading region due to its advanced healthcare infrastructure and high adoption of single-use technologies, while Asia Pacific is the fastest-growing region.

Who are the top companies in the single use bioprocessing market?

The leading companies named in the report are Sartorius, Danaher (through its Cytiva and Pall subsidiaries), and Thermo Fisher Scientific.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases